Bélanger A, Hum D W, Beaulieu M, Lévesque E, Guillemette C, Tchernof A, Bélanger G, Turgeon D, Dubois S
MRC Group in Molecular Endocrinology, CHUL Research Center and Laval University, Quebec, Canada.
J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):301-10. doi: 10.1016/s0960-0760(97)00183-0.
Conjugation of compounds by glucuronidation is a pathway found in all vertebrates studied to date. Although, it is widely recognized that the liver is a major site of glucuronidation, it is now clear that extrahepatic tissues are also involved in the conjugation of compounds to which these tissues are exposed. High levels of androsterone glucuronide and androstane-3alpha,17beta-diol glucuronide found in the human prostate, breast cyst fluid and ovary follicular fluid suggest that glucuronidation of 5alpha-reduced C19 steroids occurs in these tissues. Recently, we have reported the tissue distribution of UGT2B15, which can conjugate steroids in several human extrahepatic steroid target tissues including the skin, breast and prostate. We have also isolated a new UGT2B cDNA encoding UGT2B17, that conjugates ADT which is the major 5alpha-reduced C19 steroid glucuronide in the circulation of humans. UGT2B17 is also widely distributed in several human steroid target tissues. This gene was mapped to human chromosome 4q13 and has an exon/intron structure similar to that of rat UGT2B1 and UGT2B2. Both UGT2B15 and UGT2B17, which are able to catalyze the glucuronidation of DHT, are expressed in LNCaP cells. Interestingly, glucuronidation of steroids is markedly regulated by several factors including androgens and growth factors. Treatment of LNCaP cells with dihydrotestosterone (DHT) and epidermal growth factor (EGF) caused a decrease of DHT glucuronidation and UGT2B mRNA levels. RNase protection assays showed a specific decrease of UGT2B17 transcript in LNCaP cells treated with DHT and EGF however, the level of UGT2B15 mRNA was not affected. As well, Western blot analysis demonstrated a diminution of UGT2B17 protein level in response to DHT and EGF. These results demonstrate a differential regulation of different isoforms of steroid conjugating UGTs present in human prostate LNCaP cells. In addition, UGT2B17 was shown to be more labile than UGT2B15 indicating that regulation of UGT2B17 expression would lead to a more rapid change in the level of glucuronidated steroids. Expression of exogenous UGT2B17 in LNCaP cells by gene transfer led to a significant decrease in the androgen response. This result indicates the ability of UGT enzymes to regulate the androgen response by conjugating androgens which abolishes their interaction with their receptor and facilitates their clearance from the cell. The glucuronidation of steroids by UGT enzymes is an important mechanism by which the levels of steroids is regulated in steroid target tissues.
通过葡萄糖醛酸化作用使化合物结合是迄今在所有已研究的脊椎动物中都能发现的一条途径。尽管人们普遍认为肝脏是葡萄糖醛酸化的主要场所,但现在很清楚,肝外组织也参与这些组织所接触化合物的结合过程。在人类前列腺、乳腺囊肿液和卵巢卵泡液中发现的高水平雄甾酮葡萄糖醛酸苷和雄甾烷 - 3α,17β - 二醇葡萄糖醛酸苷表明,5α - 还原C19类固醇的葡萄糖醛酸化作用发生在这些组织中。最近,我们报道了UGT2B15的组织分布,它能在包括皮肤、乳腺和前列腺在内的几种人类肝外类固醇靶组织中使类固醇结合。我们还分离出了一个编码UGT2B17的新UGT2B cDNA,它能结合雄烯二酮,而雄烯二酮是人类循环中主要的5α - 还原C19类固醇葡萄糖醛酸苷。UGT2B17也广泛分布于几种人类类固醇靶组织中。该基因被定位到人类染色体4q13,其外显子/内含子结构与大鼠UGT2B1和UGT2B2相似。能够催化双氢睾酮葡萄糖醛酸化的UGT2B15和UGT2B17在LNCaP细胞中均有表达。有趣的是,类固醇的葡萄糖醛酸化作用受到多种因素的显著调节,包括雄激素和生长因子。用双氢睾酮(DHT)和表皮生长因子(EGF)处理LNCaP细胞会导致DHT葡萄糖醛酸化作用和UGT2B mRNA水平降低。核糖核酸酶保护分析显示,在用DHT和EGF处理的LNCaP细胞中,UGT2B17转录本特异性降低,然而,UGT2B15 mRNA的水平未受影响。同样,蛋白质免疫印迹分析表明,响应DHT和EGF,UGT2B17蛋白水平降低。这些结果表明,人类前列腺LNCaP细胞中存在的类固醇结合UGT不同同工型受到差异调节。此外,UGT2B17比UGT2B15更不稳定,这表明UGT2B17表达的调节会导致葡萄糖醛酸化类固醇水平更快变化。通过基因转移在LNCaP细胞中表达外源性UGT2B17导致雄激素反应显著降低。这一结果表明,UGT酶能够通过结合雄激素来调节雄激素反应,从而消除它们与受体的相互作用并促进其从细胞中清除。UGT酶对类固醇的葡萄糖醛酸化作用是在类固醇靶组织中调节类固醇水平的重要机制。